We conducted a randomized, controlled, multicenter, phase II study to evaluate the immunogenicity and safety of an investigational intradermal (ID) trivalent influenza vaccine (TIV) and a high-dose (HD) intramuscular (IM) TIV in older adults (≥65 years of age). Older adult subjects were ...
Sanofi received approval for Efluelda, a high-dose influenza vaccine for the elderly, in Korea. Efluelda is the first high-dose influenza vaccine approved in Korea for the elderly, preventing influenza caused by type A and B virus strains in individuals aged 65 and older. According to Sanofi...
Frail, elderly residents of long-term-care facilities (LTCFs) who received the high-dose inactivated influenza vaccine (HD IVV) during the 2011 to 2012 and 2012 to 2013 influenza seasons produced more robust immune responses to all strains of influenza when compared with residents who received st...
High-dose influenza vaccine cost effective in high-risk adultsNo Abstract available for this article.doi:10.1007/s40274-017-4347-3NoneSpringer International PublishingPharmacoeconomics & Outcomes News
We examined the safety and immunogenicity of high dose influenza vaccine (HD) compared to standard dose vaccine (SD) in participants with RA receiving stable TNFi.A randomized, double-blinded, Phase II study was conducted in adults with RA receiving TNFi, and healthy, gender and age-matched ...
Today, Sanofi announced an investment of approximately $925 million (CAD) in a new vaccine manufacturing facility at its existing site in Toronto, Canada
This randomized clinical trial compares the effect of high-dose vs standard-dose influenza vaccine on all-cause mortality and hospitalizations due to
Results from a new study suggest that high-dose influenza vaccine is associated with lower risk for hospitalizations in kidney failure patients on dialysis. The findings appear in an upcoming issue of the Clinical Journal of the American Society of Nephr
(HealthDay)—HIV-infected adults achieve higher rates of seroprotection when immunized with a high-dose of the influenza trivalent vaccine compared to the standard dose, according to a study published in the Jan. 1 issue of the Annals of Internal Medicin
BACKGROUND HIV-infected persons have less robust antibody responses to influenza vaccines.OBJECTIVE To compare the immunogenicity of high-dose influenza vaccine with that of standard dosing in HIV-positive participants.DESIGN Randomized, double-blind, controlled trial. (ClinicalTrials.gov: NCT01262846)SETT...